Thursday 16 October, 2025
Objectives: CYP2C9 and VKORC1 variant genotypes are associated with increased sensitivity to warfarin. CYP2C9 mediates the majority of the clearance…
Read morePoster: Drug/Disease Modelling - Absorption & PBPK
Characterization of the hepatic distribution of oligonucleotide therapeutics using a cross-species biologics PBPK model
Thursday 16 October, 2025
Introduction: Oligonucleotide therapeutics represent a promising novel treatment modality that has gained wide traction in the past few years due…
Read moreDevelopment of a physiologically-based pharmacokinetic model of enzalutamide, a strong CYP3A4 inducer
Thursday 16 October, 2025
Introduction: Enzalutamide (Xtandi®) is a second-generation androgen receptor inhibitor and is approved in more than 40 countries for treating patients…
Read morePharmacokinetic Simulation Study: Exploring Lamotrigine’s Impact Across Diverse Patient Populations
Thursday 16 October, 2025
Introduction: The Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved lamotrigine for treating various central nervous…
Read moreLactation related milk volume changes: implementation in a PBPK cow model for oxytetracycline
Thursday 16 October, 2025
Objectives: Lactation is a complex physiological process that is influenced by various factors, including maternal physiology, lactation stage, and milk…
Read moreA Whole-body Mechanistic Physiologically-based Pharmacokinetic Modeling of Intravenous Iron
Thursday 16 October, 2025
Introduction: Iron is essential for every cell of the mammalian organism. Iron deficiency, with or without anemia, is frequent worldwide,…
Read moreApplication of physiologically-based kinetic (PBK) modeling in revealing the role of the bile-salt efflux pump (BSEP) in bosentan-induced cholestasis
Thursday 16 October, 2025
Objectives: In Western countries, drug-induced liver injury (DILI) has been the major source of acute liver failure [1,2]. When DILI…
Read moreA minimal PBPK mice model to support the preclinical development of drugs against tuberculosis.
Thursday 16 October, 2025
Objectives: Tuberculosis is an infectious disease that every year infects and kills millions of people worldwide [1]. The standard of care,…
Read morePhysiologically based pharmacokinetic modelling to investigate the impact of obesity on the pharmacokinetics of rilpivirine, efavirenz, and etravirine
Thursday 16 October, 2025
Introduction: Nowadays, obesity represents a major public health problem [1]. The number of people affected by this disease is rising…
Read moreCabotegravir pharmacokinetics after oral and intramuscular administration using physiologically based pharmacokinetic modelling
Thursday 16 October, 2025
Introduction: Combined antiretroviral treatments have transformed HIV infection into a chronic disease. However, the efficacy of antiretroviral treatments relies on…
Read more